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Glycogen synthase kinase 3 (GSK-3), a proline/serine protein kinase ubiquitously expressed and involved inmany cellular signaling
pathways, plays a key role in the pathogenesis of Alzheimer’s disease (AD) being probably the link between β-amyloid and tau
pathology. A great eﬀort has recently been done in the discovery and development of diﬀerent new molecules, of synthetic and
natural origin, able to inhibit this enzyme, and several kinetics mechanisms of binding have been described. The small molecule
called tideglusib belonging to the thiadiazolidindione family is currently on phase IIb clinical trials for AD. The potential risks and
benefits of this new kind of disease modifying drugs for the future therapy of AD are discussed in this paper.
1. Introduction
After more than a century from its discovery and several
decades of intensive research, the cause of Alzheimer’s disease
(AD) remains yet unknown [1]. As a consequence, it is very
diﬃcult to discover and/or develop eﬀective therapies. For
this reason, current therapies are mostly palliative and there
exists a significant unmet medical need in the treatment of
this devastating condition.
Diﬀerent etiological hypotheses for AD origin have been
considered in the last thirty years focused partially on the
different histopathological lesions found in the brain of AD
patients. The first one was the cholinergic hypothesis that
considers the disease as a consequence of a deficit in the
neurotransmitter acetylcholine. It is implicated in the cog-
nitive process and consequently to its decline [2]. Although
this strategy has severe limitations, drug research in this field
has succeeded and today we have on the market four of the
five drugs currently approved for the palliative treatment
of AD based on drug research following this hypothesis
[3]. The acetylcholinesterase inhibitors produced a slight
enhancement in patient’s cognitive abilities that partially
improve temporarily their quality of life, but, in fact, the
neurodegenerative disease does not stop [4].
In the eighties the amyloid cascade hypothesis emerged,
and it was the most long considered theory [5]. It is based on
the β-amyloid overproduction as responsible for the senile
plaque formation and for the neurotoxicity that leads to the
progressive neuronal death. However, controversial data
about if β-amyloid is the cause of the disease or one of the
main risk factors for AD are reported [6]. This dilemma
is more pronounced recently because of the phase III clin-
ical trials failure of the compounds discovered and developed
based on amyloid hypothesis, such tramiprosate [7], taren-
flurbil [8], and semagacestat [9].
The third postulated theory at the end of the past cen-
tury was the tau-based hypothesis [10]. It is based on aber-
rant tau protein, a microtubule-associated protein that sta-
bilizes the neuronal cytoskeleton, as the origin of AD pa-
thology. As the time estimated to develop a new drug is
around fifteen years, there is no time yet to see what hap-
pened with drugs specifically developed based on this hy-
pothesis. Currently there are two phase IIb clinical trials with
two diﬀerent compounds, tideglusib and methylene blue.
Both compounds have reported some positive results in the
increase of cognitive level of AD patients after the first treat-
ments on phase IIa clinical trials [11, 12]. In the meanwhile,
intensive research on the physiology and pathology of tau
protein leads to the discovery of two kinases responsible for
its posttranslational aberrant modifications. After cloning,
these kinases were identified more than ten years ago, as the
well-known glycogen synthase kinase 3 (GSK-3) and cyclin
2 International Journal of Alzheimer’s Disease
dependent kinase 5 (CDK-5), as the enzymes responsible for
aberrant hyperphosphorylation of tau protein [13].
2. The GSK-3 Hypothesis for AD
In the last years a proposed alternative theory postulated
that GSK-3 may play a more instigative role in the etiology
of AD, being the link between β-amyloid and tau protein
[14]. It has been suggested that aberrant wnt or insulin sig-
naling results in increased GSK-3 function, and this could
be responsible for the observed hyperphosphorylation of tau
and the formation of neurofibrillary tangles. This point is
of utmost importance when growing evidence considered
AD as diabetes type III, which means that a deficit of brain
insulin signaling is the cause of AD [15]. In addition, elevated
GSK-3 activity may induce increased β-amyloid formation
through its action on γ-secretase and thereby give rise to
the primary neuropathological lesion observed in AD, the
senile plaques [16]. GSK-3 has also been demonstrated to
be involved in the mechanism underlying memory and
learning, and dysregulation of the enzyme function may
explain some of the early cognitive deficiencies observed in
AD [17]. Moreover, overactivity of GSK-3 activates microglia
through diﬀerent cell signaling pathways involving, among
others, NFκB and leading to the neuronal death [18]. Today
there is no doubt about the GSK-3 upregulation in the brains
of AD patients, and it is not clear if an overactivation and/or
overexpression is the cause of its exacerbated activity [19].
All these observations point directly to GSK-3 as an excellent
target to eﬀectively treat all the clinical symptoms present in
this devastating neurodegenerative disease. Currently, GSK-3
inhibitors represent promising disease modifying agents for
AD neurodegeneration [20], a disease aﬀecting the brain of
the patients and the heart of their caregivers.
3. GSK-3 Inhibitors as Drugs for Alzheimer’s
Disease: Risk versus Benefits
GSK-3 is a proline-directed serine/threonine kinase. It aﬀects
the phosphorylation of a wide range of substrates and is
involved in the regulation of many and diverse cellular func-
tions, including metabolism, diﬀerentiation, proliferation,
and apoptosis. GSK-3 is constitutively active, ubiquitous, and
essential for life as it is demonstrated inmany studies [21]. Its
basal activity is regulated by many diﬀerent mechanisms of
action including phosphorylation at diﬀerent residues (lead-
ing to inactive or superactive enzyme functions), protein-
protein interactions, and inhibition by endogenous peptides
[22]. Our organism is prepared to restore, through com-
pensative mechanism of action, a deficit in the expression
and/or activity of the enzyme [23]. However, it is not able
to downregulate GSK-3 with an endogenous alternative
mechanism of action when this enzyme is exacerbated in
diﬀerent pathological conditions such as AD or diabetes type
II. Thus, a smooth inhibition of GSK-3 able to restore levels
of activity to physiological ones would be enough to produce
an important therapeutic eﬀect.
Moreover, GSK-3 is also known to play a key role in glu-
cose metabolism and was first identified as the enzyme re-
sponsible for aﬀecting the inhibitory phosphorylation of gly-
cogen synthase (GS). This inhibitory eﬀect leads to the re-
duction of rate conversion of glucose to glycogen, giving
rise to elevations in blood glucose levels [24]. This function
is controlled by insulin that through its binding to its re-
ceptor leads indirectly to activation of protein kinase B
and subsequent phosphorylation of a key serine residue in
the N-terminal domain of GSK-3 inactivating its function
[25]. The major mechanism by which insulin stimulates the
activity of GS in skeletal muscle is inactivation of GSK-
3. Insulin treatment causes about a 50% inhibition of
GSK-3 activity, a level suﬃcient to activate GS in skeletal
muscle. Diﬀerent experiments using ATP-competitive GSK-
3 inhibitors showed insulin sensitization without elevation of
β-catenin levels. These data suggested that mild inhibition of
GSK-3 (30–40%) may be suﬃcient for insulin sensitization
while a much more degree of inactivation (>75%) of GSK-3
may be required for invoking growth-promoting eﬀects [26].
An unrelated mechanism of GSK-3 inhibition operates
in the wnt signaling cascade, a cellular pathway involved in
controlling cell fate, diﬀerentiation, and proliferation. In this
system, GSK-3 is complexed with APC, axin, and β-catenin,
as well as other proteins [22]. When the wnt system is in a
nonstimulated state, GSK-3 phosphorylates axin and APC,
the eﬀect of which is to create a more tightly associated
complex. CK1, which is also associated with this protein
assembly, performs an initial phosphorylation of β-catenin,
and then, as priming substrate for GSK-3, it is hyperphos-
phorylated by this last enzyme resulting in its dissociation
from the complex and its subsequent ubiquitination and
destruction by proteasome. However, following binding of
wnt ligands to their receptors, axin is displaced from the
complex with GSK-3 as a result of binding of the latter
to FRAT peptide, frequently rearranged in advanced T-
cell lymphomas [27]. This leads to the dissociation of the
destruction complex, the consequence of which is that β-
catenin is no longer eﬀectively phosphorylated and degraded.
Cytosolic accumulation of β-catenin promotes its transloca-
tion to the nucleus where it binds to DNA and produces the
transcription of certain oncogenes. This fact may raise the
primary concern for GSK-3 targeted therapeutics and relate
to the potential to induce transformation of nonmalignant
cells or exacerbate preexisting malignancies through their
actions on β-catenin. However, several in vivo experiments
do not confirm this risk [28].
Apparently GSK-3 inhibition may be associated with
significant mechanism-based toxicities, potentially ranging
from hypoglycemia to tumorigenesis. However, it is worth
mentioning that lithium has been used as standard therapeu-
tic for the treatment of bipolar disorder since the 1950s. This
agent is a weak inhibitor of GSK-3 that exerts its eﬀect in
vivo through a mixed mechanism of direct inhibition and
activation of PKC-α, the latter of which leads to increased
GSK-3Ser9/21 phosphorylation, the inactivated enzyme
state. At therapeutic doses, lithium is estimated to inhibit
approximately a 25% of total GSK-3 activity, and this
inhibition degree has not been associated with hypoglycemia,
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Figure 1: non-ATP competitive GSK-3 inhibitors.
increased levels of tumorigenesis, or deaths from cancer.
These epidemiological data are the most compelling argu-
ment for the potential safety of GSK-3 inhibitors, even
considering that the final resulting in vivo GSK-3 inhibition
through direct and indirect mechanism of action produced
by the GSK-3 inhibitor treatment should be smooth and
not greater than 25% of total activity. This means that, in
pathological conditions, the GSK-3 inhibitor would be able
to decrease the upregulation of the enzyme and, in the
case that this treatment would slow down the GSK-3
physiological levels, other compensatory mechanisms of
action would play the restorative function.
Another important challenge for a GSK-3 inhibitor as
an AD treatment is its specific brain distribution. The drug
needs to cross the blood-brain barrier to exert its action in
the regulation of exacerbated GSK-3 brain levels. Usually this
is not an easy task for any kind of drug, moreover when
oral bioavailability is the preferred administration route for
chronic AD treatment. It is very diﬃcult to balance the
equilibrium between molecular lipophilicity to enter into
the brain and molecular hydrophilicity to be orally admin-
istrated, and this reason has ruled out several promising
GSK-3 inhibitors from the race to the market. In addition,
having suitable brain-to-plasma ratios may be determinant
in achieving an adequate therapeutic index by limiting the
peripheral exposure required to drive CNS eﬃcacy. Once
more, a smooth GSK-3 inhibitor is here required because
in that case plasma levels of the GSK-3 inhibitor should not
decrease more than 25% of physiological enzyme activity to
avoid adverse and toxic eﬀects.
4. ATP versus Non-ATP Competitive GSK-3
Inhibitors as Drugs
Over the past ten years a number of chemically diverse
families of GSK-3 inhibitors have been discovered. They have
been reviewed periodically [29, 30]. The structural chemical
diversity of compounds reported in this area has expanded
considerably, especially in the patent literature, showing
the great interest and expectation that this new kind of
powerful drugs has arisen both in pharmaceutical and
academic laboratories [31]. However, the great majority of
these compounds compete with the ATP in their binding to
GSK-3.
Human kinome is formed by more than 500 kinases with
a more or less conserved site for binding the ATP, a common
phosphate donor molecule used by all of them in their phos-
phorylating physiological function [32]. Thus, GSK-3 inhib-
itors that are non-ATP competitive are potentially attractive
for several reasons, first of all because they may show
better cellular and in vivo potency in comparison with com-
petitive inhibitors having comparable absorption-distribu-
tion-metabolism-excretion (ADME) properties due to the
absence of endogenous ATP competition. In addition, much
better kinase selectivity may be expected from inhibitors that
bind outside the ATP pocket. Moreover, this kind of kinase
inhibitors should have lower values of IC50, which in the case
of GSK-3 is not only beneficial but also necessary to avoid
toxicity. Thus, non-ATP competitive GSK-3 inhibitors arise
as the unique real potential drugs for the treatment of at least
chronic diseases as AD.
4 International Journal of Alzheimer’s Disease
Ro31–8220
N
N S
OO
R
T D Z D s 
O O
NH
N
Me
N
S
H
N
NH2
R
Figure 2: Common features between Ro31–8220 and TDZDs.
There are few GSK-3 inhibitor families reported with
non-ATP competitive mechanism of action (Figure 1). The
first one was the thiadiazolidindione family (TDZDs) [33].
TDZD-8, commercially available from diﬀerent sources, has
been one of the most useful pharmacological tools in the
chemical genetic approach followed by many scientists to ex-
plore GSK-3 functions, as it is reflected in the great number
of published manuscripts on the field using this small mol-
ecule [34, 35]. More important for AD therapy, and prob-
ably for society, is tideglusib, a TDZD compound currently
on phase IIb clinical trials for AD and the rare tauopathy
called progressive supranuclear palsy (PSP).
In addition to TDZDs, two marine natural compounds,
the alkaloid manzamine [36] and the sesquiterpene palin-
urin, have been reported as cell permeable non-ATP com-
petitive GSK-3 inhibitors able to reduce tau phosphorylation
in cell cultures [37]. The binding site of manzamine has
been recently postulated by molecular modeling studies as
an allosteric site at the back of ATP site, just in the junction
of C-terminal and N-terminal globes of GSK-3, being the
first GSK-3 allosteric modulator described [38]. At the
moment, nothing is known about the potential binding site
of palinurin although some quantitative structure activity
relationship has been reported [39]. These compounds are
valuable candidates, with privileged scaﬀolds provided by the
nature, to be considered for further optimization of synthet-
ic, biological, and ADME properties in a drug development
process.
Another promising group of GSK-3 inhibitors is those
specifically designed to interact with the priming substrate
site present on GSK-3 [40]. The ability of GSK-3 for binding
to prephosphorylated (priming) substrates and introduce a
new phosphate group in the fourth amino acid from the
priming site has been considered by Eldar-Finkelman group
to provide substrate competitive GSK-3 inhibitors all of
which are based on peptide scaﬀolds [41]. The small peptide
L803-mts has proven to be eﬀective in decreasing the early
depressive behavior induced by mild traumatic brain injury
[42] and in the improvement of glucose homeostasis in obese
mice (ob/ob), an animal model of type II diabetes [43].
Finally, irreversible inhibitors of GSK-3 have just been
reported representing a good alternative to avoid resistance
in a future drug treatment as it is the case in other
therapeutic areas as cancer where the therapy with protein
kinase inhibitors is more advanced [44]. Halomethylketones
(HMKs) are irreversible inhibitors with IC50 values in the low
micromolar range, able to decrease tau phosphorylation in
cell cultures, good kinase and neurotransmitter selectivity,
and ability to cross the blood-brain barrier [45, 46]. GSK-3
inhibitor VII, commercially available, belongs to this class of
compounds, and it is yet used in chemical genetic approaches
for the study of GSK-3. Important is the fact that biophysical
methods such mass spectrometry and the use of these last
pharmacological tools have proven experimental data to
show that Cys199 of GSK-3 is a key amino acid to modulate
its activity [47], opening new opportunities for the future
design of specific and valuables inhibitors.
5. TDZDs: GSK-3 Inhibitors in Clinical
Trials for AD
As mentioned before, the TDZDs were the first non-ATP
GSK-3 inhibitors reported in the literature [33]. The inhib-
itory kinase activity of TDZDs was discovered in a GSK-3-
directed program initiated in the late nineties in the Me-
dicinal Chemistry Institute, CSIC. This activity was deter-
mined in a radiometric assay incubating together rabbit
recombinant GSK-3β enzyme, the peptide derived from the
sequence of the human glycogen synthase GS-1 as substrate,
and [γ-32P]ATP in the appropriate buﬀer and temperature
[48]. When the GSK-3 inhibition for the known PKC inhib-
itor Ro31–8220 was reported [49], we decided to include in
our screening program some of the side products obtained
in our laboratory in the synthesis of biological active com-
pounds such as potassium channel openers [50], muscarinic
agonist [51], or acetylcholinesterase inhibitors [52]. The
main reason for this decision was the common features
present in the chemical structure of TDZDs and Ro31–
8220, mainly the 1,3-dicarbonyl moiety in a five-membered
ring with a nitrogen atom between both carbonyl groups
(Figure 2). The results of the screening showed that three
of the four compounds tested had an IC50, the compound
concentration that inhibits 50% of the enzyme activity, in the
low micromolar range [53]. After the discovery of TDZDs as
GSK-3 inhibitors, diﬀerent compounds with the maleimide
core were reported as inhibitors of this versatile enzyme
[54, 55], pointing out the relevance of this 1,3-dicarbonyl
substitution joined by a nitrogen atom in a pentagonal ring
for the interaction with GSK-3. Our extensive SAR studies
showed that the thiadiazolidine scaﬀold is the best one to
interact with GSK-3 [56].
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All the work done in the hit to lead process and lead
selection has been reported recently [57], and currently
the clinical development of the most advanced candidate,
called tideglusib and previously known as NP031112 or NP-
12, is sponsored by a Spanish biotechnological company.
In summer 2010, data from the phase II clinical trial of
tideglusib were reported showing a trend in the cognition
increase of the twenty mild to moderate AD patients treated
for 24 weeks [58]. Now, clinical phase IIb trial is ongoing
and the orphan drug status has been achieved for the
development of tideglusib in the rare tauopathy PSP [59].
The recruitment of patients is closed and the results are
expected by the end of this year.
In preclinical studies, the compound has shown an im-
portant neuroprotective eﬀect using a kainate excitotoxicity
model and i.c.v. and oral administration [60]. Moreover,
very relevant for the future benchmark to clinical translation
to AD patients are the results obtained in the chronic oral
treatment for 3 months performed with tideglusib to the
double transgenic APP×tau rodent model [61]. An increase
in cognition using the Morris water maze test was observed
after the treatment while all the histopathological features
present on the mice brain related to AD pathology were
reduced, such as the β-amyloid plaque load, the hyperphos-
phorylation of tau protein, the gliosis, and, what it is more
important, the number of neuron deaths both in cortex
and hippocampus [62]. Very interesting is the fact recently
reported regarding the increase of insulin growth factor 1
(IGF-1) in mice brains, both in wild-type and APP×PS1
mice, after oral treatment with NP-12 for five days [63]. IGF-
1 is a potent neurotrophic peptide with therapeutic value
for many neurodegenerative diseases including AD pathol-
ogy [64]. These increased IGF-1 levels in mice would mean
that there is not only a direct action of GSK-3 inhibitors
in the brain and there is also an eﬀect on some peripheral
signalling pathways (as activation of the IGF-1 transporter
megalin) that could be modified with this innovative treat-
ment improving the AD pathology.
6. Conclusions
Clear evidence, both in cell and animal models and in AD
brain patients, points to GSK-3 as one of the key players with
a unique pivotal role in AD pathology. As the upregulation
of the enzyme is the fatal cause for neurodegeneration, its
inhibitors arise without any doubt as promising drugs
for a future disease modifying treatment [65]. Some data
suggested that smooth inhibition of the enzyme, not more
than 25%, is enough to restore the overactivated levels in
the brain to the normal function and it is not too much to
promote alternative physiological mechanism to compensate
the 25% downactivity in other tissues with normal GSK-3
function.
Although two of the GSK-3 inhibitors which entered the
clinical trials in the last five years failed in the first phases
of development, it is clear that it was caused by the intrinsic
toxicity of these two compounds related to their chemical
structure, the potent inhibition on the enzyme, and the ATP
competitiveness in their binding to GSK-3. In themeanwhile,
NP-12 (tideglusib), the unique ATP noncompetitive GSK-
3 inhibitor that entered the clinical trials in May 2006,
advances adequately in its long way to become an eﬀective
and accessible drug. Moreover, the great interest arising
in GSK-3 inhibitors has led to the search for GSK-3 as
a potential biomarker not only to follow the treatment
progression but also to stratify the patients for better clinical
trials design, and it could be possible to diagnose correctly
and on time AD neuropathology [66]. All together locate
GSK-3 inhibitors in the next horizon for AD treatment.
Acknowledgments
The authors gratefully acknowledge the financial support
of Ministry of Science and Innovation MICINN (Project
SAF2009-13015-C02-01) and Instituto de Salud Carlos III
ISCiii Project no. RD07/0060/0015 (RETICS program). D. I.
Perez acknowledges a postdoctoral fellowship from the CSIC
(JAE program). There is no commercial conflict to declare.
References
[1] S. C. Marques, C. R. Oliveira, T. F. Outeiro, and C. M. Pereira,
“Alzheimer’s disease: the quest to understand complexity,” The
The Journal of Alzheimer’s Disease, vol. 21, no. 2, pp. 373–383,
2010.
[2] J. Micheau and A. Marighetto, “Acetylcholine and memory:
a long, complex and chaotic but still living relationship,”
Behavioural Brain Research, vol. 221, no. 2, pp. 424–429, 2011.
[3] E. Giacobini, “Cholinesterase inhibitors stabilize Alzheimer
disease,” Neurochemical Research, vol. 25, no. 9-10, pp. 1185–
1190, 2000.
[4] M. Shanks, M. Kivipelto, R. Bullock, and R. Lane, “Cholin-
esterase inhibition: is there evidence for disease-modifying
eﬀects?” Current Medical Research and Opinion, vol. 25, no. 10,
pp. 2439–2446, 2009.
[5] D. J. Selkoe, “Alzheimer’s disease: genotypes, phenotype, and
treatments,” Science, vol. 275, no. 5300, pp. 630–631, 1997.
[6] R. A. Armstrong, “The molecular biology of senile plaques
and neurofibrillary tangles in Alzheimer’s disease,” Folia
Neuropathologica, vol. 47, no. 4, pp. 289–299, 2009.
[7] D. Saumier, A. Duong, D. Haine, D. Garceau, and J. Sam-
palis, “Domain-specific cognitive eﬀects of tramiprosate in
patients withmild tomoderate Alzheimer’s disease: ADAS-cog
subscale results from the alphase study,” Journal of Nutrition,
Health & Aging, vol. 13, no. 9, pp. 808–812, 2009.
[8] B. Vellas, “Tarenflurbil for Alzheimer’s disease: a “shot on
goal” that missed,” The Lancet Neurology, vol. 9, no. 3, pp. 235–
237, 2010.
[9] N. F. Schor, “What the halted phase III γ-secretase inhibitor
trial may (or may not) be telling us,” Annals of Neurology, vol.
69, no. 2, pp. 237–239, 2011.
[10] K. Iqbal and I. Grundke-Iqbal, “Molecular mechanism of
Alzheimer’s neurofibrillary degeneration and therapeutic
intervention,” Annals of the New York Academy of Sciences, vol.
777, pp. 132–138, 1996.
[11] T. Del Ser, “Phase IIa clinical trial on Alzheimer’s disease with
NP12, a GSK-3 inhibitor,” in Alzheimer’s Dementia, vol 6, p
S147, 2010.
[12] D. I. Perez, C. Gil, and A. Martinez, “Tau protein kinases
inhibitors: from the bench to the clinical trials,” in Emerging
6 International Journal of Alzheimer’s Disease
Drugs and Targets for Alzheimer’s Disease, A.Martinez, Ed., vol.
1, pp. 173–194, Royal Society of Chemistry, 2010.
[13] F. Plattner, M. Angelo, and K. P. Giese, “The roles of cyclin-
dependent kinase 5 and glycogen synthase kinase 3 in tau
hyperphosphorylation,” The Journal of Biological Chemistry,
vol. 281, no. 35, pp. 25457–25465, 2006.
[14] C. Hooper, R. Killick, and S. Lovestone, “The GSK3 hypothesis
of Alzheimer’s disease,” Journal of Neurochemistry, vol. 104, no.
6, pp. 1433–1439, 2008.
[15] S. M. de la Monte, M. Tong, N. Lester-Coll, M. Plater Jr.,
and J. R. Wands, “Therapeutic rescue of neurodegeneration
in experimental type 3 diabetes: relevance to Alzheimer’s
disease,” The Journal of Alzheimer’s Disease, vol. 10, no. 1, pp.
89–109, 2006.
[16] A. Takashima, M. Murayama, O. Murayama et al., “Presenilin
1 associates with glycogen synthase kinase-3beta and its
substrate tau,” Proceedings of the National Academy of Sciences
of the United States of America, vol. 95, no. 16, pp. 9637–9641,
1998.
[17] A. Takashima, “Drug development targeting the glycogen
synthase kinase-3beta (GSK-3beta)-mediated signal transduc-
tion pathway: role of GSK-3beta in adult brain,” Journal of
Pharmacological Sciences, vol. 109, no. 2, pp. 174–178, 2009.
[18] H. Z. Wang, J. Brown, and M. Martin, “Glycogen synthase
kinase 3: a point of convergence for the host inflammatory
response,” Cytokine, vol. 53, no. 2, pp. 130–140, 2011.
[19] K. Leroy, Z. Yilmaz, and J. P. Brion, “Increased level of
active GSK-3beta in Alzheimer’s disease and accumulation
in argyrophilic grains and in neurones at diﬀerent stages
of neurofibrillary degeneration,” Neuropathology and Applied
Neurobiology, vol. 33, no. 1, pp. 43–55, 2007.
[20] A. Martinez and D. I. Perez, “GSK-3 inhibitors: a ray of
hope for the treatment of Alzheimer’s disease?” The Journal
of Alzheimer’s Disease, vol. 15, no. 2, pp. 181–191, 2008.
[21] E. M. Hur and F. Q. Zhou, “GSK3 signalling in neural
development,” Nature Reviews Neuroscience, vol. 11, no. 8, pp.
539–551, 2010.
[22] C. Xu, N. G. Kim, and B. M. Gumbiner, “Regulation of protein
stability by GSK3 mediated phosphorylation,” Cell Cycle, vol.
8, no. 24, pp. 4032–4039, 2009.
[23] M. Bouskila, M. F. Hirshman, J. Jensen, L. J. Goodyear,
and K. Sakamoto, “Insulin promotes glycogen synthesis in
the absence of GSK3 phosphorylation in skeletal muscle,”
American Journal of Physiology, vol. 294, no. 1, pp. E28–E35,
2008.
[24] S. E. Nikoulina, T. P. Ciaraldi, S. Mudaliar, P. Mohideen,
L. Carter, and R. R. Henry, “Potential role of glycogen
synthase kinase-3 in skeletal muscle insulin resistance of type
2 diabetes,” Diabetes, vol. 49, no. 2, pp. 263–271, 2000.
[25] S. E. Nikoulina, T. P. Ciaraldi, S. Mudaliar, L. Carter, K.
Johnson, and R. R. Henry, “Inhibition of glycogen synthase
kinase 3 improves insulin action and glucose metabolism in
human skeletal muscle,” Diabetes, vol. 51, no. 7, pp. 2190–
2198, 2002.
[26] J. R. Woodgett, “Glycogen synthase kinase 3: an introductory
synopsis,” in Glycogen Synthase Kinase 3 (GSK-3) and Its
Inhibitors, A. Martinez, A. Castro, and M. Medina, Eds., pp.
3–23, John Wiley & Sons, Hoboken, NJ, USA, 2006.
[27] D. Wu and W. Pan, “GSK3: a multifaceted kinase in Wnt
signaling,” Trends in Biochemical Sciences, vol. 35, no. 3, pp.
161–168, 2010.
[28] T. D. Gould, N. A. Gray, and H. K. Manji, “Eﬀects of a
glycogen synthase kinase-3 inhibitor, lithium, in adenomatous
polyposis coli mutantmice,” Pharmacological Research, vol. 48,
no. 1, pp. 49–53, 2003.
[29] S. Phukan, V. S. Babu, A. Kannoji, R. Hariharan, and V.
N. Balaji, “GSK3beta: role in therapeutic landscape and
development of modulators,” British Journal of Pharmacology,
vol. 160, no. 1, pp. 1–19, 2010.
[30] A.Martinez, “Preclinical eﬃcacy onGSK-3 inhibitors: towards
a future generation of powerful drugs,” Medicinal Research
Reviews, vol. 28, no. 5, pp. 773–796, 2008.
[31] A. Martinez, A. Castro, I. Dorronsoro, and M. Alonso,
“Glycogen synthase kinase 3 (GSK-3) inhibitors as new
promising drugs for diabetes, neurodegeneration, cancer, and
inflammation,” Medicinal Research Reviews, vol. 22, no. 4, pp.
373–384, 2002.
[32] P. Bamborough, D. Drewry, G. Harper, G. K. Smith, and K.
Schneider, “Assessment of chemical coverage of kinome space
and its implications for kinase drug discovery,” Journal of
Medicinal Chemistry, vol. 51, no. 24, pp. 7898–7914, 2008.
[33] A. Martinez, M. Alonso, A. Castro, C. Perez, and F. J.
Moreno, “First non-ATP competitive glycogen synthase kinase
3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD)
as potential drugs for the treatment of Alzheimer’s disease,”
Journal of Medicinal Chemistry, vol. 45, no. 6, pp. 1292–1299,
2002.
[34] L. Dugo, M. Collin, and C. Thiemermann, “Glycogen synthase
kinase 3 beta as a target for the therapy of shock and inflam-
mation,” Shock, vol. 27, no. 2, pp. 113–123, 2007.
[35] M. L. Guzman, X. J. Li, C. A. Corbett et al., “Rapid and
selective death of leukemia stem and progenitor cells induced
by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine,
3,5 dione (TDZD-8),” Blood, vol. 110, no. 13, pp. 4436–4444,
2007.
[36] M. Hamann, D. Alonso, E. Martin-Aparicio et al., “Glycogen
synthase kinase-3 (GSK-3) inhibitory activity and structure-
activity relationship (SAR) studies of the manzamine alka-
loids. Potential for Alzheimer’s disease,” Journal of Natural
Products, vol. 70, no. 9, pp. 1397–1405, 2007.
[37] D. Alonso and A. Martinez, “Marine compounds as a new
source for glycogen synthase kinase 3 inhibitors,” in Glycogen
Synthase Kinase 3 (GSK-3) and Its Inhibitors, A. Martinez, A.
Castro, andM.Medina, Eds., pp. 307–331, JohnWiley & Sons,
Hoboken, NJ, USA, 2006.
[38] J. Peng, S. Kudrimoti, S. Prasanna et al., “Structure-activity
relationship and mechanism of action studies of manzamine
analogues for the control of neuroinflammation and cerebral
infections,” Journal of Medicinal Chemistry, vol. 53, no. 1, pp.
61–76, 2010.
[39] G. Ermondi, G. Caron, I. G. Pintos et al., “An application
of two MIFs-based tools (Volsurf+ and Pentacle) to binary
QSAR: the case of a palinurin-related data set of non-ATP
competitive Glycogen Synthase Kinase 3[beta] (GSK-3[beta])
inhibitors,” European Journal of Medicinal Chemistry, vol. 46,
no. 3, pp. 860–869, 2011.
[40] H. Eldar-Finkelman, A. Licht-Murava, S. Pietrokovski, andM.
Eisenstein, “Substrate competitive GSK-3 inhibitors—strategy
and implications,” Biochimica et Biophysica Acta, vol. 1804, no.
3, pp. 598–603, 2010.
[41] H. Eldar-Finkelman and M. Eisenstein, “Peptide inhibitors
targeting protein kinases,” Current Pharmaceutical Design, vol.
15, no. 21, pp. 2463–2470, 2009.
[42] M. Shapira, A. Licht, A. Milman, C. G. Pick, E. Shohami, and
H. Eldar-Finkelman, “Role of glycogen synthase kinase-3 beta
in early depressive behavior induced by mild traumatic brain
International Journal of Alzheimer’s Disease 7
injury,” Molecular and Cellular Neuroscience, vol. 34, no. 4, pp.
571–577, 2007.
[43] O. Kaidanovich-Beilin and H. Eldar-Finkelman, “Long-term
treatment with novel glycogen synthase kinase-3 inhibitor
improves glucose homeostasis in ob/ob mice: molecular
characterization in liver and muscle,” Journal of Pharmacology
and Experimental Therapeutics, vol. 316, no. 1, pp. 17–24,
2006.
[44] C. P. Belani, “The role of irreversible EGFR inhibitors in the
treatment of non-small cell lung cancer: overcoming resistance
to reversible EGFR inhibitors,” Cancer Investigation, vol. 28,
no. 4, pp. 413–423, 2010.
[45] S. Conde, D. I. Perez, A. Martinez, C. Perez, and F. J.
Moreno, “Thienyl and Phenyl alpha-halomethyl ketones:
new inhibitors of glycogen synthase kinase (GSK-3 beta)
from a library of compound searching,” Journal of Medicinal
Chemistry, vol. 46, no. 22, pp. 4631–4633, 2003.
[46] D. I. Perez, S. Conde, C. Perez et al., “Thienylhalomethylke-
tones: irreversible glycogen synthase kinase 3 inhibitors as use-
ful pharmacological tools,” Bioorganic & Medicinal Chemistry,
vol. 17, no. 19, pp. 6914–6925, 2009.
[47] D. I. Pe´rez, V. Palomo, C. Pe´rez et al., “Switching reversibility
to irreversibility in GSK-3 inhibitors: clues for specific design
of new compounds,” Journal of Medicinal Chemistry, vol. 54,
no. 12, pp. 4042-4056, 2011.
[48] J. R. Woodgett, “Use of peptide substrates for aﬃnity purifi-
cation of protein-serine kinases,” Analytical Biochemistry, vol.
180, no. 2, pp. 237–241, 1989.
[49] I. Hers, J. M. Tavare, and R. M. Denton, “The protein kinase
C inhibitors bisindolylmaleimide I (GF 109203x) and IX (Ro
31-8220) are potent inhibitors of glycogen synthase kinase-3
activity,” FEBS Letters, vol. 460, no. 3, pp. 433–436, 1999.
[50] A. Martinez, A. Castro, I. Cardelus, J. Llenas, and J. M.
Palacios, “Arylimino-1,2,4-Thiadiazolidinones: a new family
of potassium channel openers,” Bioorganic &Medicinal Chem-
istry, vol. 5, no. 7, pp. 1275–1283, 1997.
[51] A. Martinez, D. Alonso, A. Castro et al., “Synthesis and poten-
tial muscarinic receptor binding and antioxidant properties
of 3-(thiadiazolyl)pyridine 1-oxide compounds,” Archiv der
Pharmazie, vol. 332, no. 6, pp. 191–194, 1999.
[52] A. Martinez, E. Fernandez, A. Castro et al., “N-benzylpiperi-
dine derivatives of 1,2,4-thiadiazolidinone as new acetylcho-
linesterase inhibitors,” European Journal of Medicinal Chem-
istry, vol. 35, no. 10, pp. 913–922, 2000.
[53] A. Martinez, A. Castro, C. Perez et al., “Heterocyclic inhibitors
of glycogen synthase kinase 3,” WO01/85685.
[54] H. C. Zhang, H. Ye, B. R. Conway et al., “3-(7-Azaindolyl)-
4-arylmaleimides as potent, selective inhibitors of glycogen
synthase kinase-3,” Bioorganic & Medicinal Chemistry Letters,
vol. 14, no. 12, pp. 3245–3250, 2004.
[55] T. A. Engler, S. Malhotra, T. P. Burkholder et al., “The
development of potent and selective bisarylmaleimide GSK3
inhibitors,” Bioorganic & Medicinal Chemistry Letters, vol. 15,
no. 4, pp. 899–903, 2005.
[56] A. Martinez, M. Alonso, A. Castro et al., “SAR and 3D-
QSAR studies on thiadiazolidinone derivatives: exploration
of structural requirements for glycogen synthase kinase 3
inhibitors,” Journal of Medicinal Chemistry, vol. 48, no. 23, pp.
7103–7112, 2005.
[57] A. Martinez, M. Alonso, A. Castro, and I. Dorronsoro, “GSK-3
inhibitors in Alzheimer’s disease: TDZDs, from the discovery
to clinical trials,” in Medicinal Chemistry of Alzheimer Disease,
A. Martinez, Ed., pp. 225–253, Transworld Research Network,
Kerala, India, 2008.
[58] http://www.noscira.com/prensa.cfm?mS=237&mSS=616.
[59] http://clinicaltrials.gov/ct2/show/NCT01049399?term=tidegl-
usib&rank=1.
[60] R. Luna-Medina, M. Cortes-Canteli, S. Sanchez-Galiano et al.,
“NP031112, a thiadiazolidinone compound, prevents inflam-
mation and neurodegeneration under excitotoxic conditions:
potential therapeutic role in brain disorders,” Journal of Neu-
roscience, vol. 27, no. 21, pp. 5766–5776, 2007.
[61] E. M. Ribe, M. Perez, B. Puig et al., “Accelerated amyloid
deposition, neurofibrillary degeneration and neuronal loss
in double mutant APP/tau transgenic mice,” Neurobiology of
Disease, vol. 20, no. 3, pp. 814–822, 2005.
[62] L. Sereno, M. Coma, M. Rodriguez et al., “A novel GSK-3 beta
inhibitor reduces Alzheimer’s pathology and rescues neuronal
loss in vivo,” Neurobiology of Disease, vol. 35, no. 3, pp. 359–
367, 2009.
[63] M. Bolos, S. Fernandez, and I. Torres-Aleman, “Oral adminis-
tration of a GSK3 inhibitor increases brain insulin-like growth
factor I levels,” The Journal of Biological Chemistry, vol. 285,
no. 23, pp. 17693–17700, 2010.
[64] I. Torres-Aleman, “Targeting insulin-like growth factor-1 to
treat Alzheimer’s disease,” Expert Opinion on Therapeutic
Targets, vol. 11, no. 12, pp. 1535–1542, 2007.
[65] M. Medina and J. Avila, “Glycogen synthase kinase-3 (GSK-3)
inhibitors for the treatment of Alzheimer’s disease,” Current
Pharmaceutical Design, vol. 16, no. 25, pp. 2790–2798, 2010.
[66] A. Hye, F. Kerr, N. Archer et al., “Glycogen synthase kinase-
3 is increased in white cells early in Alzheimer’s disease,”
Neuroscience Letters, vol. 373, no. 1, pp. 1–4, 2005.
